(Q54578237)

English

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

author name string

Eveline Boucher

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Yan Rolland

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Elodie Vauléon

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Marc Pracht

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Christophe Perrin

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Catherine Le Roux

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Jean-Luc Raoul

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

language of work or name

0 references

publication date

28 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

118

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

147-156

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Biology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results 1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Change in contrast enhancement of HCC on 1-month follow-up CT after local radiotherapy: an early predictor of final treatment response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Post-treatment imaging of liver tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Response evaluation of gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

21 January 2018

Vascularity of Hepatocellular Carcinoma: Assessment with Contrast-enhanced SecondHarmonic versus Conventional Power Doppler US

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

7 January 2021

based on heuristic

inferred from DOI database lookup

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26255

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26255

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21713764

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54578237&oldid=1424912209"